Proxima

About Proxima

Proxima is at the forefront of medical innovation, specializing in the programming of protein interactions to unlock new therapeutic possibilities. They serve the pharmaceutical and biotechnology industries, empowering drug discovery with a proprietary integrated platform that combines phase-shifting technologies like Inducers, Modulators, and Blockers. Demonstrating significant industry validation, Proxima recently secured an $80 million seed funding round led by DCVC, underscoring their potential to advance AI-driven drug discovery. The company actively seeks talent for roles at the 'bleeding edge of artificial intelligence,' suggesting a forward-thinking approach to team building.